At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,026 enrolled
Drug / intervention
Alogliptin and Metformin hydrochloridedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Specified Drug-Use Survey of Alogliptin and Metformin Hydrochloride Combination Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Renal or Hepatic Impairment or Advanced Age"
In Brief
An observational study evaluating Alogliptin and Metformin hydrochloride for Type 2 Diabetes Mellitus. Completed, enrolled 1,026 participants across 1 site.
Detailed Summary
The purpose of this survey is to evaluate the long-term safety and efficacy of the alogliptin and metformin hydrochloride combination tablet in type 2 diabetes mellitus patients with renal impairment (mild), hepatic impairment (mild or moderate), or advanced age (65 years and more) in the routine clinical setting.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesJapan
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
Enrollment StartFeb 2017
First PostedJun 2018
Primary CompletionOct 2019
TodayJul 2026
First PostedJun 13, 2018
Enrollment StartFeb 28, 2017
Primary CompletionOct 31, 2019
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 8.1 years ago
Interventions
Alogliptin and Metformin hydrochloridedrug
Alogliptin and Metformin hydrochloride combination tablets